Evidence map›Paper›PMID 30518375›Full record

ArticleJournal of translational medicine2018

Immunological effects of the intraparenchymal administration of allogeneic and autologous adipose-derived mesenchymal stem cells after the acute phase of middle cerebral artery occlusion in rats.

Zhang Yu, Tang Wenyan, Su Xuewen, Dong Baixiang, Wang Qian, Wang Zhaoyan, Yang Yinxiang, Qu Suqing, Luan Zuo

Abstract read
In one paragraph

Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhang YuDepartment of Pediatrics, Navy General Hospital, No. 6, Fucheng Road, Haidian District, Beijing, 100048, China.
Tang WenyanDepartment of Pediatrics, Navy General Hospital, No. 6, Fucheng Road, Haidian District, Beijing, 100048, China.
Su XuewenDepartment of Pediatrics, Navy General Hospital, No. 6, Fucheng Road, Haidian District, Beijing, 100048, China.
Dong BaixiangBeijing Yinfeng Dingcheng Bioengineering Technology Co., Ltd., No. 14, Zhonghe Street, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing, 100176, China.
Wang QianDepartment of Pediatrics, Navy General Hospital, No. 6, Fucheng Road, Haidian District, Beijing, 100048, China.
Wang ZhaoyanDepartment of Pediatrics, Navy General Hospital, No. 6, Fucheng Road, Haidian District, Beijing, 100048, China.
Yang YinxiangDepartment of Pediatrics, Navy General Hospital, No. 6, Fucheng Road, Haidian District, Beijing, 100048, China.
Qu SuqingDepartment of Pediatrics, Navy General Hospital, No. 6, Fucheng Road, Haidian District, Beijing, 100048, China.
Luan ZuoDepartment of Pediatrics, Navy General Hospital, No. 6, Fucheng Road, Haidian District, Beijing, 100048, China. luanzuo@aliyun.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdipose-derived mesenchymal stem cell (ADMSC) therapy can promote recovery from cerebral ischemia; however, more information regarding appropriate sources of ADMSCs is required. This study was aimed at analyzing the immunogenicity of rat ADMSCs by comparing the immunological effects of intraparenchymal administration of allogeneic ADMSCs (allo-ADMSCs) and autologous ADMSCs (auto-ADMSCs) after the acute phase of middle cerebral artery occlusion (MCAO) in rats.

methodsAllo- or auto-ADMSCs from rats (1 × 10

resultsCompared with allo-ADMSCs, auto-ADMSCs showed lower immunogenicity and evoked weaker immunological responses. Allo-ADMSCs evoked significantly stronger protein expression of interleukin-2 and interferon-gamma, as well as the local accumulation of CD4+ T lymphocytes, CD8+ T lymphocytes, and microglial cells. This indicates that auto-ADMSCs may contribute to higher survival rates, longer survival time, wider migratory scope, and fewer apoptotic cells. In addition, a small number of transplanted auto-ADMSCs expressed astrocyte-like and neuron-like markers 28 days after transplantation. We did not observe surviving transplanted allo-ADMSCs at this time point. We also found that auto-ADMSCs induced a greater degree of functional recovery and a greater reduction in infarct volume than allo-ADMSCs 28 days after transplantation.

conclusionsAuto-ADMSCs were more effective than allo-ADMSCs in promoting recovery and reducing the infarct volume of MCAO rats. This could be associated with better viability, migratory ability, and differentiation potential, as well as a lower rate of apoptosis. Confirmation of the superiority of auto-ADMSCs and clarification of the underlying mechanisms will provide a theoretical basis for the improved clinical treatment of cerebral infarction.

Indexed as

Mesenchymal Stem Cell TransplantationAdipose TissueAnimalsAntigens, CDApoptosisAstrocytesBiomarkersBrain IschemiaCell MovementCell ShapeCell SurvivalCoculture TechniquesHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInfarction, Middle Cerebral ArteryMesenchymal Stem CellsAntigens, CDBiomarkersHistocompatibility Antigens Class IHistocompatibility Antigens Class IIAdipose tissue-derived stem cellsAllogeneicAutologousFocal cerebral infarctTransplantation

Identifiers

PMID30518375
PMCPMC6280522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.